

However, this invention pertains to the creation of a specific 2.4 kb gene cassette that includes a specific gene that confers resistance to aminoglycoside antibiotics, increases protein levels inside a cell and increases yield of production of recombinant proteins, when inserted. In particular, the inventors have identified a specific gene *aadA1* (adenyltransferase gene) that codes for a 28.876 Kd protein that normally confers aminoglycoside resistance to cells. Further, the inventors have found that a "gene cassette" carrying the *aadA1* gene which when transferred to bacterial strains induces enhancement of protein production and accumulation. Additionally, this inducement is not restricted by the nature of the vector, induction system or nature of protein. In short, the invention provides a method of reconstruction of a cell for increased yield of recombinant protein, which involves a "one-step procedure of induction of a new gene into the cell." Therefore, the technology may have a substantial commercial value to the pharmaceutical industry.

In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.

#### **Endothelial Protective Actions of Cytochrome P450 Epoxygenase-derived Eicosanoids**

Darryl C. Zeldin (NIEHS), *et al.*  
U.S. Patent Application No. 09/634,369 filed 09 Aug 2000, notice of allowance issued (DHHS Reference No. E-252-1999/0-US-02).

*Licensing Contact:* Marlene Shinn-Astor; (301) 435-4426; [shinnm@mail.nih.gov](mailto:shinnm@mail.nih.gov).

Cytochrome P450s catalyze the NADPH-dependent oxidation of arachidonic acid to various eicosanoids found in several species including humans. The eicosanoids are biosynthesized in numerous tissues including pancreas, intestine, kidney, heart, and lung where they are involved in many different biological activities.

The NIH announces a new therapy wherein epoxyeicosatrienoic acid (EET) compositions have been found to be useful in preventing endothelial cell death due to hypoxia-reoxygenation. Given that endothelial injury is an important early event in the development of the atherosclerotic plaque and is associated with myocardial dysfunction in ischemic heart disease, reduced EET levels are speculated to be involved in the pathogenesis of these cardiovascular disorders.

This research is described in *Yang et al.*, *Molecular Pharmacology* 60: 310-320, 2001.

#### **T-Cell Receptor Alternate Reading Frame Protein, (TARP) and Uses Thereof**

Ira Pastan, Magnus Essand, Byungkook Lee, George Vasmatazis, Ulrich Brinkman, Paul Duray, and Curt Wolfgang (NCI).

U.S. Patent Application No. 10/031,158 filed 11 Jan 2002, and multiple National Stage foreign filings (DHHS Reference No. E-104-1999/2).

*Licensing Contact:* Brenda Hefti; (301) 435-4632; [heftib@mail.nih.gov](mailto:heftib@mail.nih.gov).

This invention relates to a tumor-associated protein, TARP, which is expressed in breast and prostate cancer cells. This antigen target might be a useful tool for the diagnosis and treatment of breast and prostate cancer. TARP has shown efficacy in vivo as a potential therapeutic for the treatment of cancer. TARP has been the subject of several publications, including: *J. Biol. Chem.* (2004 Jun 4) 279(23):24561-24568, Epub 2004 Mar 29 as doi:10.1074/jbc.M402492200; *Cancer Res.* (2004 Apr 1) 64(7):2610-2618; *Endocrinology* (2003 Aug) 144(8):3433-40; *Cancer Res.* (2001 Nov 15) 61(22):8122-8126; *Proc. Natl. Acad. Sci. USA* (2000 Aug 15) 97(17):9437-9442.

In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.

#### **Method for Reducing the Immunogenicity of Antibody Variable Domains**

Eduardo Padlan (NIDDK) *et al.*  
U.S. Patent No. 6,797,492 issued 28 Sep 2004 (DHHS Ref. No. E-163-1991/2-US-02)

*Licensing Contact:* Jeff Walenta; (301) 435-4633; [walentaj@mail.nih.gov](mailto:walentaj@mail.nih.gov).

The current invention addresses a limitation of monoclonal antibodies used in immunotherapy. Monoclonal antibodies with high selectivity for human antigens are commonly produced in mice. However, when introduced into humans for therapy, the antibodies can be neutralized by the human immune system and their duration and effectiveness limited. Modification of non-human antibodies to avoid the human immune system often produces antibodies with reduced affinity for the antigen and which remain antigenic in humans.

The current invention provides a method for producing "humanized" antibodies that retain antigen binding

properties but which have eliminated or reduced antigenicity. The method comprises substituting residues in the variable region of the non-human antibody with residues found in the variable region of human antibodies, with particular emphasis on residues that are solvent exposed and that are not adjacent to complementarity determining regions.

When tested in monkeys, the serum longevity of the "veneered" antibodies produced by the current invention was significantly greater than that of mouse antibodies or chimeric mouse-human antibodies. Accordingly, the technology could enhance the effectiveness of monoclonal antibodies designed for therapy of cancer or other diseases.

Dated: March 25, 2005.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 05-6896 Filed 4-6-05; 8:45 am]

**BILLING CODE 4140-01-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Eye Institute; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Eye Institute Special Emphasis Panel, Loan Repayment Program Applications.

*Date:* April 18, 2005.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate loan Repayment applications.

*Place:* Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW., Washington, DC 20015.

*Contact Person:* Anne Schaffner, PhD, Scientific Review Administrator, Division of Extramural Research, National Eye Institute, 5635 Fishers Lane, Suite 1300, MSC 9300, Bethesda, MD 20892-9300, (301) 451-2020, [aes@nei.nih.gov](mailto:aes@nei.nih.gov).

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.867, Vision Research, National Institutes of Health, HHS)

Dated: March 31, 2005.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 05-6873 Filed 4-6-05; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Eye Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Eye Institute Special Emphasis Panel, Visual Screening in Preschoolers (U10).

*Date:* April 11, 2005.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Holiday Inn Select Bethesda, 8120 Wisconsin Ave., Bethesda, MD 20814.

*Contact Person:* Samuel Rawlings, PhD, Chief, Scientific Review Branch, Division of Extramural Research, National Eye Institute, 5635 Fishers Lane, Suite 1300, MSC 9300, Bethesda, MD 20892-9300, 301-451-2020.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.867, Vision Research, National Institutes of Health, HHS)

Dated: March 31, 2005.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 05-6877 Filed 4-6-05; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Human Genome Research Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Council for Human Genome Research.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Advisory Council for Human Genome Research.

*Date:* May 23-24, 2005.

*Open:* May 23, 2005, 8:30 a.m. to 12 p.m.

*Agenda:* Discuss matters of program relevance.

*Place:* National Institutes of Health, 5635 Fishers Lane, Bethesda, MD 20892.

*Closed:* May 23, 2005, 1 p.m. to 5 p.m. on May 24, 2005.

*Agenda:* To review and evaluate grant applications and/or proposals.

*Place:* National Institutes of Health, 5635 Fishers Lane, Bethesda, MD 20892.

*Contact Person:* Mark S. Guyer, PhD, Director for Extramural Research, National Human Genome Research Institute, 5635 Fishers Lane, Suite 4076, MSC 9305, Bethesda, MD 20892, 301-496-7531, [guyerm@mail.nih.gov](mailto:guyerm@mail.nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: <http://www.genome.gov/11509849>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program No. 93.172, Human Genome Research, National Institutes of Health, HHS)

Dated: March 30, 2005.

**La Verne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 05-6886 Filed 4-6-05; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Deafness and Other Communication Disorders; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Deafness and Other Communication Disorders Advisory Council.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Deafness and Other Communication Disorders Advisory Council.

*Date:* May 20, 2005.

*Open:* 8:30 a.m. to 11:30 a.m.

*Agenda:* Staff reports on divisional, programmatic and special activities.

*Place:* National Institutes of Health, Building 31, 31 Center Drive, Conference Room 10, Bethesda, MD 20892.

*Closed:* 11:30 a.m. to 3 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Building 31, 31 Center Drive, Conference Room 10, Bethesda, MD 20892.

*Contact Person:* Craig A. Jordan, PhD, Director, Division of Extramural Activities, NIDCD, NIH, Executive Plaza South, Room 400C, 6120 Executive Blvd., Bethesda, MD 20892-7180, 301-496-8693, [jordanc@nidcd.nih.gov](mailto:jordanc@nidcd.nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the